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In 1973-74 Breast Cancer Detection Demonstration Projects (BCDDP) were
initiated at 29 locations around the country under the auspices of the National
Cancer Institute and the American Cancer Society. Theirpurpose was to demon-
strate the feasibility ofperiodic screening oflarge numbers ofwomen for breast
cancer, usingclinicalhistory, physicalexamination, mammography, andthermog-
raphy. Followinginception ofthis program, however, questions were raisedabout
the relative values ofthe screening components when compared to possible risks
involvedwiththeionizingradiationfrommammography. Criticssuggestedthatthe
radiation used todetect cancers might also induce malignancies atalaterdate. No
concern was expressed orintendedregarding the obvious value andimportance of
diagnostic x-ray examination ofthe breast in women with signs and/or symptoms
which might be related to breast cancer.
In October 1975, the National Cancer Institute appointed three experts to lead
investigations into various aspectsoftheseissues, byanalysis ofdatageneratedby
astudyconductedbytheHealthInsurancePlan(HIP)ofGreaterNewYork,which
beganin 1963. AgroupheadedbyDr. LesterBreslowofUCLAwastoexaminethe
benefits as determined by the HIP Study results; a group chaired by Dr. Arthur
Upton, at the time Dean of Basic Sciences, Health Sciences Center, State
University of New York, Stony Brook, was to consider and estimate radiation
risks; and a group headed by Dr. Louis Thomas of NIH was to reexamine the
pathology ofcancers found in the HIP Study. Subsequently-in January 1977-a
working group under Dr. Oliver Beahrs of the Mayo Clinic, was charged with
reviewing in-depth the findings generated by the BCDDP.
Recently, the National Institutes of Health and the National Cancer Institute
convened a meeting, the NIH/NCI Consensus Development Meeting on Breast
Cancer Screening, with the objective ofdeveloping a set ofrecommendations on
themajorissues andquestions whichhavearisenconcerningbreastcancerscreen-
ing and the BCDDP, including mammography.
The Panel (see Appendix) appointed to deliberate on these issues met in open
forum at NIH on September 14, 15, and 16, 1977, and reviewed the reports ofthe
fourstudygroupsmentionedabove,heardtestimonyfrominterestedprofessionals,
associations, BCDDPprojectdirectors, andmembersofthepublic. Thequestions,
and asummary ofthe recommendations formulatedbythePanel,follow.1
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1Throughout its deliberations, the Panel repeatedly emphasized the distinction between mammography used for
diagnosis-thevalueofwhichwasnotinquestion-and mammographic screeningtodetectpossiblediseaseinwomen
who have no symptoms or physical findings whatsoever.
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QUESTION 1: Is there evidence that early detection of breast cancer leads to
reduced mortality frombreastcancer? Whichofthe available screeningmodalities
or combination of modalities is most effective in early detection?
ANSWER: The only sound scientific evidence which demonstrates a favorable
benefit inbreast cancerscreeningisderivedfromtheHIPStudy. Thedatafromthis
randomized controlled trial-which formed the rationale and stimulus for the
BCDDP-indicate that periodic breast cancer screening can decrease the number
ofdeaths due tobreast cancerbyabout40%oinwomenwho are over50yearsofage.
The age suggests that this may be related to menopause but the data in the HIP
Study do not permit any definition ofthis question. However, the HIP Study thus
far shows no decrease in breast cancer mortality attributable to screening women
below the age of 50.
The evidence indicates that the benefit ofthe screeningprogram rests onthe use
ofphysikal examination and mammography, in combination. The Panel noted that
there are no rigorous scientific datashowing to what extenteitherphysical examin-
ation alone or mammography alone may be beneficial. The efficacy ofphysical
examination as ascreeningprocedure forbreast cancer(e.g.,bywell-trained nurse
practitioners) has not been examined.
The Panel acknowledged that mammographic techniques have improved mark-
edly in recent years, with smaller, and presumably earlier, lesions now being
detected. The advantage ofmammography lies in the fact thatappropriatetherapy
may be administered at an earlier stage of breast cancer, presumably improving
prognosis. Moreover, radiation dosage has been decreased significantly. Nonethe-
less, there are insufficient data to indicate that these advances have resulted in
decreased mortality for women under age 50 at the time of screening.
QUESTION 2: What are the risks ofeach ofthe available screening modalities for
early detection of breast cancer?
ANSWER: Neitherphysical examination nortechniques such as thermography or
ultrasound are known to haveharmfuleffects uponthebody. Theuse ofmammog-
raphy, however, is associated with an inherent risk of radiation exposure, and
studies indicate that breast tissue is particularly susceptible to radiation damage.
The precise radiation risk is difficult to quantify, but current evidence strongly
suggests that risk increases linearly with increasing dose and is lineardown to the
lowest dose.
At the present time, the average surface radiation exposure in the BCDDP
centers is 1.2(0.2 to2.5) roentgens. Itis estimated thateveryradofexposureraises
awoman's riskofbreast cancerbyabout 1%. Thus, ifawomaninthegeneralpopu-
lationhasabouta7%chanceofdevelopingbreastcancerinherlifetime, oneradwill
increase her risk by 1% of7%, orfrom 7% to 7.07%. ThePanelobserved that even
with the cumulative dose that would result from a series offive yearly mammo-
grams in theBCDDP-about4rads total with the newertechniques-the increased
risk of breast cancer is so little that it could not be demonstrated in long-term
follow-up studies of the BCDDP group.
With repeated examinations of one cohort of women, the likelihood offinding
new cancers progressively declines afterprevalent cancers are detected while the
total radiationgiveneach womanprogressively rises. Thisputs anobviouslimit on
the advisability ofrepeated rescreening of the same population.
QUESTION 3: Dothepotentialrisks versus benefitsdifferfordifferentmethodsof
breast cancer detection and at different ages ofpatients screened?
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ANSWER: The question ofrisk, in this context, applies only to mammography.
Data from several studies indicate that the risk ofradiation, in general, may de-
crease with age although data from the analysis of A-Bomb survivors show an
excess of cancer in the age group over 50. Data suggest that the peak age of
susceptibility is between 10 and 19 years and that the danger drops gradually
thereafter. This possibility, too, argues for confining radiation, in this case mam-
mography, to older age groups, but there is no conclusive evidence.
QUESTION 4: Ifit is notpossible to answer any or all ofthe foregoing questions,
what data need to be generated to provide adequate answers?
ANSWER: New diagnostic/screening techniques are needed. The Panel recom-
mended greater emphasis on research with noninvasive techniques, such as
thermography, ultrasound, and biologic markers.
Becausethepotentialbenefitsofthermography remainundocumented,thePanel
recommended that thermography be discontinued as a routine partofthe BCDDP
screeningprogram exceptinthose centers where sufficientexpertise isavailable to
justify further clinical investigation and research. Because thermography in the
BCDDP was not set up as a research study, its continued use should require the
development of a research design.
The Panel deplored the lackofclear-cut dataon the efficacy andthe risk-benefit
ratioofscreeningforwomenunder50, buttheydidnotcometoanagreementabout
the feasibility and logistics of randomized clinical trials to resolve such issues.
However, clinical trials would be important in order to resolve certain questions
concerning the efficacy ofperiodic breast screening.
The BCDDP should continue to monitor all women in whom breast cancer has
beendiagnosed. AlthoughthePanelwasunabletoassessthefeasibilityoffollowing
all womenwhohave hadamammogram intheBCDDP, there seemedtobegeneral
agreement that such followup would be important and that this question deserves
further consideration.
QUESTION 5: What are th-e practical and ethical considerations forimplementing
demonstrationprojects incancerdetection andhowdoestheBCDDPcomplywith
these considerations?
ANSWER: Demonstration programs by definition utilize proven and practical
methods toproject new information to the medical community. However, from its
inception the BCDDP has ofnecessity incorporated certain practices ofassumed
but unconfirmed value.
As a demonstration program with investigational components, therefore, the
BCDDP must come to grips with several important ethical concerns. The Panel
recommended that the BCDDP's Informed Consent Form indicate the radiation
dosage tobedelivered tothepatient, andassurethatallinformationgainedthrough
the programwillbe disclosed tothe screenee, as well as toherphysician.
The Panel proposed that the screenee receive the Informed Consent Form and
appropriate backgroundmaterials beforehand, sothatshewould beable todiscuss
the proposed procedure with her family and her physician.
The Panel recommended that the histology of any lesion smaller than one
centimeter in diameter, or any papillary or intraductal proliferation originally
interpreted asmalignant, bereviewed.by atleasttwopathologistspriortodefinitive
therapy.
Womenwhohavebeenscreenedalreadyandwhohavehadadiagnosisofcancer
should be notified promptly ifthere has been a change in diagnosis.
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Any new experimental study should take into consideration avariety ofissues,
e.g., itsjustification from a cost-benefit point ofview, the informed consent pro-
cess, the way in which research subjects are selected, and the development of
guidelines forcompensationofindividualparticipantswhoareinjuredinthecourse
ofthe study. Furthermore, more women, both professional and consumer repre-
sentatives, should be included in the design and planning of any future studies.
QUESTION 6: What can the Consensus Panel recommend as to the type and fre-
quency ofbreast cancerscreening andwhoshouldprovidethescreening?
ANSWER: Based on the available evidence, with the understanding that no new
participants are being added to the program and that limits be set on radiation
exposure, the Panel recommended the BCDDP screening, using mammography
and physical examination in combination, be continued for those women 50 and
older who are currently enrolled. Regardless of the location for mammographic
screening, upper limits should be set on radiation exposure consistent with best
current data. Women subjected tomammography should askforsuch information
and should be urged to maintain their own personal exposure records.
ThePanelfoundnoconvincingjustificationforroutinemammographicscreening
forwomenundertheageof50. Thisdoesnotimply,however,thatphysicalexamin-
ation and breast self-examination are not important for women at any age.
The Panel recommended that routine mammography for women 40 through 49
enrolled in the BCDDPbe restricted to women having apersonalhistoryofbreast
cancer, or whose mothers or sisters have a history ofbreast cancer.
Mammographic screening of women below the age of 40 should be limited to
those women having a personal history ofbreast cancer.
Ethical considerations, however, led thePanel to concede thatwomen under50
who are alreadyparticipating inthe BCDDP shouldbeaffordedtheopportunity to
continuehavingmammogramsiftheywish-solongastheyareinformedthatthere
is noprovenbenefitandthere ispresumed risk, andthatthePaneldoesnotrecom-
mend screening mammography in this age group. (Again, the Panel went to great
lengthtodistinguishbetweenmammographicscreeningandmammographyusedas
adiagnostic tool. Thus, forexample, ifawomanunderthe ageof50intheBCDDP
develops symptoms orfindings suggestive ofbreast cancer, she may well require
mammographic examinations as part of her medical evaluation by her own
physician).
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